Abstract
Effective non-genetic disease modifying treatments for Huntington’s disease (HD) will necessarily target multiple diverse neurodegenerative processes triggered by mutant huntingtin. Neurotrophin receptors are well-positioned for this task as they regulate signaling pathways that largely overlap with signaling networks contributing to HD-related synaptic dysfunction, glial activation, excitotoxicity, and other degenerative processes. This review will discuss the contributions of disrupted neurotrophin receptor-related signaling to primary HD neuropathologies, and prospects for harnessing this signaling to develop therapeutics to counteract HD degenerative mechanisms. Application of the native protein ligands has been challenging pharmacologically, but progress has been made with the advent of small molecule compounds that can selectively bind to and activate specific Trk receptors or p75NTR to promote trophic and/or inhibit degenerative signaling in cell populations preferentially affected in HD.
CNS & Neurological Disorders - Drug Targets
Title:Neurotrophin Receptor Signaling as a Therapeutic Target for Huntington's Disease
Volume: 16 Issue: 3
Author(s): Danielle A. Simmons, Frank M. Longo and Stephen M. Massa*
Affiliation:
- Department of Neurology, San Francisco VAMC and UCSF, MS127, San Francisco, CA 94121,United States
Abstract: Effective non-genetic disease modifying treatments for Huntington’s disease (HD) will necessarily target multiple diverse neurodegenerative processes triggered by mutant huntingtin. Neurotrophin receptors are well-positioned for this task as they regulate signaling pathways that largely overlap with signaling networks contributing to HD-related synaptic dysfunction, glial activation, excitotoxicity, and other degenerative processes. This review will discuss the contributions of disrupted neurotrophin receptor-related signaling to primary HD neuropathologies, and prospects for harnessing this signaling to develop therapeutics to counteract HD degenerative mechanisms. Application of the native protein ligands has been challenging pharmacologically, but progress has been made with the advent of small molecule compounds that can selectively bind to and activate specific Trk receptors or p75NTR to promote trophic and/or inhibit degenerative signaling in cell populations preferentially affected in HD.
Export Options
About this article
Cite this article as:
Simmons A. Danielle, Longo M. Frank and Massa M. Stephen*, Neurotrophin Receptor Signaling as a Therapeutic Target for Huntington's Disease, CNS & Neurological Disorders - Drug Targets 2017; 16 (3) . https://dx.doi.org/10.2174/1871527315666161107093047
DOI https://dx.doi.org/10.2174/1871527315666161107093047 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial:Metabolic, Pathological, and Therapeutic Perspectives Intracellular 5’-Nucleotidases.
Current Medicinal Chemistry Mechanisms of Action of Antiepileptic Drugs
Current Topics in Medicinal Chemistry Positron Emission Tomography: Applications In Drug Discovery and Drug Development
Current Topics in Medicinal Chemistry Nutraceuticals against Neurodegeneration: A Mechanistic Insight
Current Neuropharmacology MCI Patients Declining and Not-Declining at Mid-Term Follow-Up: FDG-PET Findings
Current Alzheimer Research MicroRNA-34a and its target genes: Key factors in cancer multidrug resistance
Current Pharmaceutical Design Oxidative Stress, Mitochondrial Dysfunction, and Stress Signaling in Alzheimers Disease
Current Alzheimer Research Transglutaminase Inhibition as a Possible Therapeutical Approach to Protect Cells from Death in Neurodegenerative Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Melatonin in the Biliary Tract and Liver: Health Implications
Current Pharmaceutical Design Carbohydrate-Based Bioactive Compounds for Medicinal Chemistry Applications
Mini-Reviews in Medicinal Chemistry Arterial Ischemic Stroke in Neonates and Children: Review and Current Issues
Current Pediatric Reviews Tuning and Fine-Tuning of Synapses with Adenosine
Current Neuropharmacology Neuroimaging methods in Epilepsy of Temporal Origin
Current Medical Imaging Management of Antiepileptic Treatment After Epilepsy Surgery - Practices and Problems
Current Pharmaceutical Design Drugs, Environmental Factors, Loci and Genes Involved in Nonsyndromic Orofacial Cleft
Current Pharmacogenomics Current Overview of Inorganic Nanoparticles for the Treatment of Central Nervous System (CNS) Diseases
Current Nanomaterials Kv7 Channels as Targets for the Treatment of Pain
Current Pharmaceutical Design Cannabinoids and Sensory Neurones
Current Neuropharmacology Synthetic and Natural Protease Inhibitors Provide Insights into Parasite Development, Virulence and Pathogenesis
Current Medicinal Chemistry Physiology and Pathophysiology of Na+/H+ Exchange Isoform 1 in the Central Nervous System
Current Neurovascular Research